Sarah F Cook1, Chris Stockmann2,3, Samira Samiee-Zafarghandy4,5, Amber D King1, Nina Deutsch6, Elaine F Williams4, Diana G Wilkins1,7, Catherine M T Sherwin8,9,10, John N van den Anker4,11,12,13. 1. Department of Pharmacology and Toxicology, Center for Human Toxicology, University of Utah, Salt Lake City, UT, USA. 2. Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, 295 Chipeta Way, Salt Lake City, UT, 84108, USA. 3. Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. 4. Division of Clinical Pharmacology, Children's National Health System, Washington, DC, USA. 5. Division of Neonatology, Department of Pediatrics, McMaster University, Hamilton, ON, Canada. 6. Division of Anesthesiology, Sedation, and Perioperative Medicine, Children's National Health System, Washington, DC, USA. 7. Division of Medical Laboratory Sciences, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA. 8. Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, 295 Chipeta Way, Salt Lake City, UT, 84108, USA. catherine.sherwin@hsc.utah.edu. 9. Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. catherine.sherwin@hsc.utah.edu. 10. Clinical Trials Office, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA. catherine.sherwin@hsc.utah.edu. 11. Departments of Pediatrics, Integrative Systems Biology, Pharmacology and Physiology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. 12. Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands. 13. Department of Paediatric Pharmacology, University Children's Hospital Basel, Basel, Switzerland.
Abstract
OBJECTIVES: This study aimed to model the population pharmacokinetics of intravenous paracetamol and its major metabolites in neonates and to identify influential patient characteristics, especially those affecting the formation clearance (CLformation) of oxidative pathway metabolites. METHODS: Neonates with a clinical indication for intravenous analgesia received five 15-mg/kg doses of paracetamol at 12-h intervals (<28 weeks' gestation) or seven 15-mg/kg doses at 8-h intervals (≥28 weeks' gestation). Plasma and urine were sampled throughout the 72-h study period. Concentration-time data for paracetamol, paracetamol-glucuronide, paracetamol-sulfate, and the combined oxidative pathway metabolites (paracetamol-cysteine and paracetamol-N-acetylcysteine) were simultaneously modeled in NONMEM 7.2. RESULTS: The model incorporated 259 plasma and 350 urine samples from 35 neonates with a mean gestational age of 33.6 weeks (standard deviation 6.6). CLformation for all metabolites increased with weight; CLformation for glucuronidation and oxidation also increased with postnatal age. At the mean weight (2.3 kg) and postnatal age (7.5 days), CLformation estimates (bootstrap 95% confidence interval; between-subject variability) were 0.049 L/h (0.038-0.062; 62 %) for glucuronidation, 0.21 L/h (0.17-0.24; 33 %) for sulfation, and 0.058 L/h (0.044-0.078; 72 %) for oxidation. Expression of individual oxidation CLformation as a fraction of total individual paracetamol clearance showed that, on average, fractional oxidation CLformation increased <15 % when plotted against weight or postnatal age. CONCLUSIONS: The parent-metabolite model successfully characterized the pharmacokinetics of intravenous paracetamol and its metabolites in neonates. Maturational changes in the fraction of paracetamol undergoing oxidation were small relative to between-subject variability.
OBJECTIVES: This study aimed to model the population pharmacokinetics of intravenous paracetamol and its major metabolites in neonates and to identify influential patient characteristics, especially those affecting the formation clearance (CLformation) of oxidative pathway metabolites. METHODS: Neonates with a clinical indication for intravenous analgesia received five 15-mg/kg doses of paracetamol at 12-h intervals (<28 weeks' gestation) or seven 15-mg/kg doses at 8-h intervals (≥28 weeks' gestation). Plasma and urine were sampled throughout the 72-h study period. Concentration-time data for paracetamol, paracetamol-glucuronide, paracetamol-sulfate, and the combined oxidative pathway metabolites (paracetamol-cysteine and paracetamol-N-acetylcysteine) were simultaneously modeled in NONMEM 7.2. RESULTS: The model incorporated 259 plasma and 350 urine samples from 35 neonates with a mean gestational age of 33.6 weeks (standard deviation 6.6). CLformation for all metabolites increased with weight; CLformation for glucuronidation and oxidation also increased with postnatal age. At the mean weight (2.3 kg) and postnatal age (7.5 days), CLformation estimates (bootstrap 95% confidence interval; between-subject variability) were 0.049 L/h (0.038-0.062; 62 %) for glucuronidation, 0.21 L/h (0.17-0.24; 33 %) for sulfation, and 0.058 L/h (0.044-0.078; 72 %) for oxidation. Expression of individual oxidation CLformation as a fraction of total individual paracetamol clearance showed that, on average, fractional oxidation CLformation increased <15 % when plotted against weight or postnatal age. CONCLUSIONS: The parent-metabolite model successfully characterized the pharmacokinetics of intravenous paracetamol and its metabolites in neonates. Maturational changes in the fraction of paracetamol undergoing oxidation were small relative to between-subject variability.
Authors: C van Ganzewinkel; L Derijks; K J S Anand; R A van Lingen; C Neef; B W Kramer; P Andriessen Journal: Acta Paediatr Date: 2014-04-15 Impact factor: 2.299
Authors: R A van Lingen; J T Deinum; J M Quak; A J Kuizenga; J G van Dam; K J Anand; D Tibboel; A Okken Journal: Arch Dis Child Fetal Neonatal Ed Date: 1999-01 Impact factor: 5.747
Authors: Elizabeth K Johnsrud; Sevasti B Koukouritaki; Karthika Divakaran; Laura L Brunengraber; Ronald N Hines; D Gail McCarver Journal: J Pharmacol Exp Ther Date: 2003-10 Impact factor: 4.030
Authors: Caroline D van der Marel; Brian J Anderson; Richard A van Lingen; Nicholas H G Holford; Marien A L Pluim; Frank G A Jansman; John N van den Anker; Dick Tibboel Journal: Eur J Clin Pharmacol Date: 2003-05-22 Impact factor: 2.953
Authors: Matthew W Linakis; Joseph E Rower; Jessica K Roberts; Eleanor I Miller; Diana G Wilkins; Catherine M T Sherwin Journal: Br J Clin Pharmacol Date: 2017-09-06 Impact factor: 4.335
Authors: Matthew W Linakis; Sarah F Cook; Shaun S Kumar; Xiaoxi Liu; Diana G Wilkins; Roger Gaedigk; Andrea Gaedigk; Catherine M T Sherwin; John N van den Anker Journal: Clin Pharmacokinet Date: 2018-10 Impact factor: 6.447
Authors: Jessica K Roberts; Matthew W Linakis; Xiaoxi Liu; Catherine M T Sherwin; John N van den Anker Journal: Br J Clin Pharmacol Date: 2018-04-17 Impact factor: 4.335
Authors: Robert B Flint; Daniella W Roofthooft; Anne van Rongen; Richard A van Lingen; Johannes N van den Anker; Monique van Dijk; Karel Allegaert; Dick Tibboel; Catherijne A J Knibbe; Sinno H P Simons Journal: Pediatr Res Date: 2017-06-21 Impact factor: 3.756
Authors: Laurent M A Favié; Floris Groenendaal; Marcel P H van den Broek; Carin M A Rademaker; Timo R de Haan; Henrica L M van Straaten; Peter H Dijk; Arno van Heijst; Jeroen Dudink; Koen P Dijkman; Monique Rijken; Inge A Zonnenberg; Filip Cools; Alexandra Zecic; Johanna H van der Lee; Debbie H G M Nuytemans; Frank van Bel; Toine C G Egberts; Alwin D R Huitema Journal: PLoS One Date: 2019-02-14 Impact factor: 3.240
Authors: Mayur K Ladumor; Deepak Kumar Bhatt; Andrea Gaedigk; Sheena Sharma; Aarzoo Thakur; Robin E Pearce; J Steven Leeder; Michael B Bolger; Saranjit Singh; Bhagwat Prasad Journal: Drug Metab Dispos Date: 2019-05-17 Impact factor: 3.922